BR112014023402B1 - Solução oftálmica compreendendo diquafosol e métodos para produção da mesma, para inibição da formação dos precipitados insolúveis na mesma, para redução da irritação ocular causada pela mesma e para aumentar a eficácia de conservação da mesma - Google Patents

Solução oftálmica compreendendo diquafosol e métodos para produção da mesma, para inibição da formação dos precipitados insolúveis na mesma, para redução da irritação ocular causada pela mesma e para aumentar a eficácia de conservação da mesma Download PDF

Info

Publication number
BR112014023402B1
BR112014023402B1 BR112014023402-7A BR112014023402A BR112014023402B1 BR 112014023402 B1 BR112014023402 B1 BR 112014023402B1 BR 112014023402 A BR112014023402 A BR 112014023402A BR 112014023402 B1 BR112014023402 B1 BR 112014023402B1
Authority
BR
Brazil
Prior art keywords
ophthalmic solution
diquafosol
chelating agent
concentration
acid
Prior art date
Application number
BR112014023402-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Akiko Sakatani
Tatsuo Ikei
Koji Inagaki
Masatsugu Nakamura
Kazuhiro Hosoi
Mikiko Saito
Masaki Sonoda
Yoko Fukui
Mitsuaki Kuwano
Original Assignee
Santen Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49259901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014023402(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Santen Pharmaceutical Co., Ltd filed Critical Santen Pharmaceutical Co., Ltd
Publication of BR112014023402B1 publication Critical patent/BR112014023402B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112014023402-7A 2012-03-26 2013-03-25 Solução oftálmica compreendendo diquafosol e métodos para produção da mesma, para inibição da formação dos precipitados insolúveis na mesma, para redução da irritação ocular causada pela mesma e para aumentar a eficácia de conservação da mesma BR112014023402B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012069157 2012-03-26
JP2012-069157 2012-03-26
PCT/JP2013/058519 WO2013146649A1 (ja) 2012-03-26 2013-03-25 ジクアホソル含有点眼液

Publications (1)

Publication Number Publication Date
BR112014023402B1 true BR112014023402B1 (pt) 2020-09-29

Family

ID=49259901

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014023402-7A BR112014023402B1 (pt) 2012-03-26 2013-03-25 Solução oftálmica compreendendo diquafosol e métodos para produção da mesma, para inibição da formação dos precipitados insolúveis na mesma, para redução da irritação ocular causada pela mesma e para aumentar a eficácia de conservação da mesma

Country Status (26)

Country Link
US (4) US9486529B2 (esLanguage)
EP (2) EP3431092A1 (esLanguage)
JP (6) JP5625081B2 (esLanguage)
KR (5) KR20200096708A (esLanguage)
CN (2) CN113018259A (esLanguage)
AU (3) AU2013241507A1 (esLanguage)
BR (1) BR112014023402B1 (esLanguage)
CA (1) CA2868390C (esLanguage)
DK (1) DK2832359T3 (esLanguage)
EA (1) EA028848B1 (esLanguage)
ES (1) ES2702575T3 (esLanguage)
GE (1) GEP20166470B (esLanguage)
HK (1) HK1204922A1 (esLanguage)
HU (1) HUE041671T2 (esLanguage)
IN (1) IN2014DN08632A (esLanguage)
MX (1) MX353874B (esLanguage)
MY (1) MY169816A (esLanguage)
NZ (1) NZ631041A (esLanguage)
PH (1) PH12014501955B1 (esLanguage)
PL (1) PL2832359T3 (esLanguage)
PT (1) PT2832359T (esLanguage)
SG (2) SG11201405799TA (esLanguage)
TR (1) TR201820073T4 (esLanguage)
TW (4) TWI723722B (esLanguage)
UA (1) UA113981C2 (esLanguage)
WO (1) WO2013146649A1 (esLanguage)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2750229B2 (ja) 1991-05-30 1998-05-13 信越石英株式会社 大型軽量化反射鏡
JP2750234B2 (ja) 1991-12-25 1998-05-13 信越石英株式会社 シリカ質軽量反射鏡の製造方法
IN2014DN08632A (esLanguage) 2012-03-26 2015-05-22 Santen Pharmaceutical Co Ltd
EP3093019B1 (en) 2014-01-10 2021-05-26 Santen Pharmaceutical Co., Ltd Pharmaceutical composition containing pyridylamino acetic acid compound
JP6104433B2 (ja) * 2015-06-05 2017-03-29 参天製薬株式会社 水性点眼液
CA2971689C (en) 2014-12-25 2020-11-03 Santen Pharmaceutical Co., Ltd. Aqueous ophthalmic solution
CN113143948A (zh) * 2015-06-05 2021-07-23 参天制药株式会社 以向佩戴有软性隐形眼镜的干眼症患者的眼中滴入的方式使用为特征的干眼症治疗剂
KR102116170B1 (ko) 2015-06-29 2020-05-27 야마사 쇼유 가부시키가이샤 P1, p4-비스(5''-우리딜)테트라포스페이트 결정의 보관 방법
JP6688057B2 (ja) * 2015-12-01 2020-04-28 日水製薬株式会社 グラム染色用後染色試液及びグラム染色方法
PH12020551313B1 (en) * 2018-02-28 2024-02-28 Santen Pharmaceutical Co Ltd Ophthalmic composition comprising diquafosol and cationic polymer
CN108403625A (zh) * 2018-04-11 2018-08-17 东莞解石医药科技有限公司 一种含有螯合剂的地夸磷索四钠滴眼液
MX2021001707A (es) * 2018-08-30 2021-04-19 Eyevance Pharmaceuticals Llc Formulaciones de lubricantes oculares.
KR20240049646A (ko) * 2019-08-27 2024-04-16 산텐 세이야꾸 가부시키가이샤 디쿠아포솔 또는 그 염 및 폴리비닐피롤리돈을 함유하는 수성 안과용 조성물
CN113720924B (zh) * 2020-05-25 2025-01-10 南京帝昌医药科技有限公司 一种地夸磷索四钠的含量及有关物质检测方法
WO2022107791A1 (ja) * 2020-11-18 2022-05-27 参天製薬株式会社 ポリヘキサメチレンビグアナイドまたはその塩を含有する水性点眼液
JPWO2022107790A1 (esLanguage) * 2020-11-18 2022-05-27
KR102548710B1 (ko) 2020-12-24 2023-06-28 주식회사 종근당 디쿠아포솔 또는 이의 약제학적으로 허용가능한 염과 토코페롤을 함유하는 건성안 예방 또는 치료용 약제학적 조성물
CN112933040A (zh) * 2021-02-04 2021-06-11 合肥博思科创医药科技有限公司 一种舒更葡糖钠注射液的制备方法
KR102794468B1 (ko) * 2022-04-04 2025-04-14 서울대학교산학협력단 감미 억제용 조성물 및 식품의 감미 억제 방법
WO2023195718A1 (ko) * 2022-04-04 2023-10-12 서울대학교산학협력단 감미 억제용 조성물 및 식품의 감미 억제 방법
JP7735925B2 (ja) * 2022-05-02 2025-09-09 株式会社三洋物産 遊技機
CN116019767A (zh) * 2023-01-12 2023-04-28 上海阿尔福斯医药科技有限公司 眼用制剂及其制备方法
CN117838628B (zh) * 2024-03-01 2024-05-28 广州市桐晖药业有限公司 一种地夸磷索钠滴眼液及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH075456B2 (ja) * 1988-10-01 1995-01-25 参天製薬株式会社 点眼液
JP2530491B2 (ja) 1988-12-20 1996-09-04 参天製薬株式会社 ヒアルロン酸点眼液
TW200402B (esLanguage) 1990-08-13 1993-02-21 Senju Pharma Co
US5504113A (en) 1994-03-02 1996-04-02 Allergan, Inc. Enhancement of benzalkonium chloride preservative activity in formulations containing an incompatible drug
US5900407A (en) 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US6348589B1 (en) 1997-02-06 2002-02-19 Inspire Pharmaceuticals, Inc. Certain dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
DK1012154T3 (da) 1997-07-25 2004-07-26 Inspire Pharmaceuticals Inc Salte af di(uridin-5'-tetraphosphat), fremgangsmåde til fremstilling og anvendelser deraf
KR19990074047A (ko) 1998-03-03 1999-10-05 김수복 콘택트렌즈용 세척, 소독 및 보존제 조성물
DE69932313T2 (de) 1998-08-21 2007-07-19 Senju Pharmaceutical Co., Ltd. Wässerige flüssige zubereitungen
JP4880808B2 (ja) * 1999-11-15 2012-02-22 久光製薬株式会社 人工涙液型点眼剤組成物
JP4003008B2 (ja) * 2000-05-30 2007-11-07 参天製薬株式会社 角膜上皮伸展促進剤
KR100832821B1 (ko) * 2000-05-30 2008-05-28 산텐 세이야꾸 가부시키가이샤 각막 상피 신장 촉진제
US6555675B2 (en) 2000-08-21 2003-04-29 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
US6583181B1 (en) 2000-11-22 2003-06-24 Lonza Inc. Antimicrobial quaternary ammonium compositions with reduced ocular irritation
JP2003160491A (ja) * 2001-09-11 2003-06-03 Santen Pharmaceut Co Ltd ジウリジンリン酸含有点眼液
CN1228053C (zh) * 2001-09-11 2005-11-23 参天制药株式会社 含有二尿苷磷酸的滴眼液
WO2003030892A1 (en) 2001-10-11 2003-04-17 Alcon, Inc. Methods for treating dry eye
RU2322980C2 (ru) 2003-04-14 2008-04-27 Уайт Холдингз Корпорейшн Композиции, содержащие пиперациллин и тазобактам, применимые для инъекции
JP4806956B2 (ja) 2004-04-20 2011-11-02 大正製薬株式会社 点眼用液剤
US20060073172A1 (en) 2004-10-01 2006-04-06 Schneider L W Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure
PT1841432E (pt) 2004-12-02 2010-10-25 Venus Remedies Ltd Composições para combater a resistência aos antibióticos mediada pela beta-lactamase usando inibidores da betalactamase úteis para injecção
KR100870104B1 (ko) * 2005-11-28 2008-11-26 주식회사 머젠스 안구건조증 치료 및 예방용 조성물
JP4168071B2 (ja) 2005-12-08 2008-10-22 興和株式会社 点眼用組成物
JP2008247828A (ja) 2007-03-30 2008-10-16 Wakamoto Pharmaceut Co Ltd ラタノプロストを含有する水性医薬組成物。
JP2009040727A (ja) * 2007-08-09 2009-02-26 Towa Yakuhin Kk ラタノプロストを有効成分とする安定な点眼液剤
CN100534423C (zh) * 2007-11-30 2009-09-02 张咏梅 一种保质期长的氯霉素滴眼液及其制备方法
US8119112B2 (en) 2008-01-31 2012-02-21 Bausch & Lomb Incorporated Ophthalmic compositions with an amphoteric surfactant and hyaluronic acid
CN101461778A (zh) * 2009-01-06 2009-06-24 河北科技大学 不含抑菌剂的盐酸环丙沙星滴眼液及其制备方法
US20100190734A1 (en) * 2009-01-23 2010-07-29 Romulus Kimbro Brazzell Method of treating dry eye disease with azithromycin
CN102100693A (zh) * 2009-12-16 2011-06-22 沈阳兴齐制药有限公司 一种含有肌肽的人工泪液及其制备方法
KR20110104367A (ko) 2010-03-16 2011-09-22 삼천당제약주식회사 무보존제 안과용 조성물
WO2012012640A1 (en) 2010-07-21 2012-01-26 Cumberland Pharmaceuticals, Inc. Acetycysteine compositions and methods of use thereof
CN106729718A (zh) 2010-09-10 2017-05-31 参天制药株式会社 以组合p2y2受体激动剂和透明质酸或其盐为特征的干眼症治疗剂
MX2013007502A (es) 2010-12-28 2013-08-01 Santen Pharmaceutical Co Ltd Solucion oftalmica que comprende diquafosol, metodo para producir la misma, y metodo para inhibir la formacion de precipitado insoluble.
EP2696876A4 (en) * 2011-04-12 2014-09-03 R Tech Ueno Ltd AQUEOUS OPHTHALMIC COMPOSITION
JP2015514705A (ja) 2012-03-26 2015-05-21 ディラフォール・アクチボラゲットＤｉｌａｆｏｒ Ａｂ 分娩停止の処置のための方法
IN2014DN08632A (esLanguage) 2012-03-26 2015-05-22 Santen Pharmaceutical Co Ltd

Also Published As

Publication number Publication date
JP7042762B2 (ja) 2022-03-28
JP6126041B2 (ja) 2017-05-10
US20150072951A1 (en) 2015-03-12
AU2013241507A1 (en) 2014-10-09
MY169816A (en) 2019-05-16
SG11201405799TA (en) 2014-11-27
TW201343196A (zh) 2013-11-01
EP2832359A4 (en) 2015-03-25
HUE041671T2 (hu) 2019-05-28
EA201491771A1 (ru) 2015-01-30
EA028848B1 (ru) 2018-01-31
JP5625081B2 (ja) 2014-11-12
SG10201607872PA (en) 2016-11-29
TWI625135B (zh) 2018-06-01
JP2019070053A (ja) 2019-05-09
JP2018076384A (ja) 2018-05-17
US10632139B2 (en) 2020-04-28
KR20150027312A (ko) 2015-03-11
CN113018259A (zh) 2021-06-25
MX353874B (es) 2018-02-01
JP7447176B2 (ja) 2024-03-11
WO2013146649A1 (ja) 2013-10-03
US20180353531A1 (en) 2018-12-13
TWI723722B (zh) 2021-04-01
KR20200096708A (ko) 2020-08-12
PL2832359T3 (pl) 2019-04-30
US10071113B2 (en) 2018-09-11
JP2013227291A (ja) 2013-11-07
KR101935484B1 (ko) 2019-01-04
US20200215093A1 (en) 2020-07-09
MX2014011468A (es) 2015-01-12
TW201806583A (zh) 2018-03-01
JP2022075813A (ja) 2022-05-18
IN2014DN08632A (esLanguage) 2015-05-22
JP2014132039A (ja) 2014-07-17
HK1206648A1 (en) 2016-01-15
AU2016201111A1 (en) 2016-03-10
KR101875845B1 (ko) 2018-07-06
CN104203254A (zh) 2014-12-10
HK1204922A1 (zh) 2015-12-11
ES2702575T3 (es) 2019-03-04
DK2832359T3 (en) 2019-02-04
KR20180079469A (ko) 2018-07-10
AU2016201110B2 (en) 2017-06-15
US9486529B2 (en) 2016-11-08
EP2832359B1 (en) 2018-11-14
JP2017119718A (ja) 2017-07-06
EP3431092A1 (en) 2019-01-23
CA2868390A1 (en) 2013-10-03
TR201820073T4 (tr) 2019-01-21
PT2832359T (pt) 2019-01-29
JP6389544B2 (ja) 2018-09-12
TWI757799B (zh) 2022-03-11
PH12014501955A1 (en) 2014-11-17
UA113981C2 (xx) 2017-04-10
EP2832359A1 (en) 2015-02-04
JP6483299B2 (ja) 2019-03-13
TWI692364B (zh) 2020-05-01
KR20190002751A (ko) 2019-01-08
US20170020910A1 (en) 2017-01-26
KR101536885B1 (ko) 2015-07-14
CA2868390C (en) 2020-03-31
TW202015704A (zh) 2020-05-01
PH12014501955B1 (en) 2022-03-09
KR20140136980A (ko) 2014-12-01
TW202041220A (zh) 2020-11-16
AU2016201110A1 (en) 2016-03-10
US11166974B2 (en) 2021-11-09
NZ631041A (en) 2016-10-28
GEP20166470B (en) 2016-04-25

Similar Documents

Publication Publication Date Title
JP7447176B2 (ja) ジクアホソル含有点眼液
BR112013016008B1 (pt) Solução oftálmica compreendendo diquafosol, método para a produção da mesma, e método para a inibição da formação de precipitado insolúvel
HK1260860A1 (en) Ophthalmic solution comprising diquafosol
HK1206648B (en) Diquafosol-containing eye drop

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/03/2013, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 11A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2767 DE 16-01-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.